-
2
-
-
0037067889
-
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study
-
Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
-
(2002)
Arch Intern Med
, vol.162
, pp. 1729-1735
-
-
Meyer, G.1
Marjanovic, Z.2
Valcke, J.3
-
3
-
-
0037775584
-
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
-
Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
-
(2003)
N Engl J Med
, vol.349
, pp. 146-153
-
-
Lee, A.Y.1
Levine, M.N.2
Baker, R.I.3
-
4
-
-
0037111563
-
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
-
Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
-
(2002)
Blood
, vol.100
, pp. 3484-3488
-
-
Prandoni, P.1
Lensing, A.W.A.2
Piccioli, A.3
-
5
-
-
0033708930
-
A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy
-
Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84:805-810.
-
(2000)
Thromb Haemost
, vol.84
, pp. 805-810
-
-
Palareti, G.1
Legnani, C.2
Lee, A.3
-
6
-
-
0033850037
-
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis
-
Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3078-3083
-
-
Hutten, B.A.1
Prins, M.H.2
Gent, M.3
-
7
-
-
4644221063
-
-
Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):401S-428S.
-
Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):401S-428S.
-
-
-
-
8
-
-
4644230820
-
-
Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):204S-233S.
-
Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):204S-233S.
-
-
-
-
9
-
-
0026726392
-
Factors affecting the maintenance dose of warfarin
-
James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45:704-706.
-
(1992)
J Clin Pathol
, vol.45
, pp. 704-706
-
-
James, A.H.1
Britt, R.P.2
Raskino, C.L.3
-
10
-
-
0036785249
-
Patient-specific factors predictive of warfarin dosage requirements
-
Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36:1512-1517.
-
(2002)
Ann Pharmacother
, vol.36
, pp. 1512-1517
-
-
Absher, R.K.1
Moore, M.E.2
Parker, M.H.3
-
11
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
-
Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
-
(2005)
N Engl J Med
, vol.352
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
-
12
-
-
0037012465
-
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
-
Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
-
(2002)
JAMA
, vol.287
, pp. 1690-1698
-
-
Higashi, M.K.1
Veenstra, D.L.2
Kondo, L.M.3
-
13
-
-
0036914221
-
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
-
Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72:702-710.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 702-710
-
-
Scordo, M.G.1
Pengo, V.2
Spina, E.3
-
14
-
-
0037194409
-
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
-
Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87:277-280.
-
(2002)
Br J Cancer
, vol.87
, pp. 277-280
-
-
Rivory, L.P.1
Slaviero, K.A.2
Clarke, S.J.3
-
15
-
-
0033812260
-
Optimizing the erythromycin breath test for use in cancer patients
-
Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res. 2000;6:3480-3485.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3480-3485
-
-
Rivory, L.P.1
Slaviero, K.2
Seale, J.P.3
-
16
-
-
0008615560
-
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer
-
Williams ML, Bhargava P, Cherrouk I, et al. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol. 2000;49:485-488.
-
(2000)
Br J Clin Pharmacol
, vol.49
, pp. 485-488
-
-
Williams, M.L.1
Bhargava, P.2
Cherrouk, I.3
-
17
-
-
0027509399
-
High clearance of (S)-warfarin in a warfarin-resistant subject
-
Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol. 1993;35:327-330.
-
(1993)
Br J Clin Pharmacol
, vol.35
, pp. 327-330
-
-
Hallak, H.O.1
Wedlund, P.J.2
Modi, M.W.3
-
18
-
-
19344366484
-
Systematic overview of warfarin and its drug and food interactions
-
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106.
-
(2005)
Arch Intern Med
, vol.165
, pp. 1095-1106
-
-
Holbrook, A.M.1
Pereira, J.A.2
Labiris, R.3
-
19
-
-
32944475687
-
An adverse interaction between warfarin and fluoropyrimidines revisited
-
Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005;5:175-180.
-
(2005)
Clin Colorectal Cancer
, vol.5
, pp. 175-180
-
-
Saif, M.W.1
-
20
-
-
0030799414
-
Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
-
Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 1997;57:4229-4235.
-
(1997)
Cancer Res
, vol.57
, pp. 4229-4235
-
-
Ren, S.1
Yang, J.S.2
Kalhorn, T.F.3
-
21
-
-
0141539462
-
Fatal cholestatic liver failure associated with gemcitabine therapy
-
Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci. 2003;48:1804-1808.
-
(2003)
Dig Dis Sci
, vol.48
, pp. 1804-1808
-
-
Robinson, K.1
Lambiase, L.2
Li, J.3
-
22
-
-
0028357278
-
Assessing random error in the international normalized ratio
-
Inciardi JF. Assessing random error in the international normalized ratio. Ther Drug Monit. 1994;16:425-426.
-
(1994)
Ther Drug Monit
, vol.16
, pp. 425-426
-
-
Inciardi, J.F.1
-
23
-
-
0017355290
-
Warfarin elimination and responsiveness in patients with renal dysfunction
-
Bachmann K, Shapiro R, Mackiewicz J. Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol. 1977;17:292-299.
-
(1977)
J Clin Pharmacol
, vol.17
, pp. 292-299
-
-
Bachmann, K.1
Shapiro, R.2
Mackiewicz, J.3
-
24
-
-
0036263813
-
Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data
-
Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251-263.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 251-263
-
-
Lee, C.R.1
Goldstein, J.A.2
Pieper, J.A.3
-
25
-
-
24944503322
-
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
-
Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751.
-
(2005)
Hum Mol Genet
, vol.14
, pp. 1745-1751
-
-
Yuan, H.Y.1
Chen, J.J.2
Lee, M.T.3
|